The number of medications available to treat diabetes continues to increase. Recently, there has been widespread interest in two classes of medications, the SGLT2 inhibitors and the GLP1 agonists. …
What To Know About Jiyoutai-china’s First Potential Ozempic Challenger
A Chinese pharmaceutical company is seeking approval to market Jiyoutai, an alternative to Ozempic that could be the first biosimilar drug to compete with Novo Nordisk’s weight-loss and diabetes drugs …
Continue Reading about What To Know About Jiyoutai-china’s First Potential Ozempic Challenger →
